AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
GoodRx Q2 Earnings Fall Short of Expectations with EPS at 4c
ByAinvest
Friday, Aug 8, 2025 5:57 am ET1min read
GoodRx reported Q2 EPS of 4c, missing consensus of 10c, and revenue of $203.1M, also below consensus of $205.71M. CEO Wendy Barnes expressed excitement about the company's progress, citing new deals with pharma and the launch of a condition subscription product for erectile dysfunction. The company aims to reduce friction in the healthcare system and serve as a complement to insurance.
GoodRx Holdings, Inc. (NASDAQ: GDRX) reported its second-quarter earnings on July 2, 2025, which fell short of analyst expectations. The company's earnings per share (EPS) of $0.04 missed the consensus estimate of $0.10, while revenue of $203.1 million was also below the expected $205.87 million [1].The medication savings platform saw a 1% year-over-year (YoY) increase in revenue, driven by a 32% growth in pharma manufacturer solutions revenue to $35.0 million. However, prescription transactions revenue decreased by 3% to $143.1 million, primarily due to a 14% decline in Monthly Active Consumers, attributed to changes in the retail pharmacy landscape, including store closures and volume reduction in integrated savings programs [2].
CEO Wendy Barnes expressed excitement about the company's progress, highlighting new deals with pharmaceutical manufacturers and the launch of a condition-specific subscription product for erectile dysfunction. This new offering aims to reduce friction in the healthcare system and serve as a complement to insurance.
Despite the near-term challenges, GoodRx expects pharma manufacturer solutions to grow as a percentage of total revenue in the near to medium term. The company forecasts adjusted EBITDA between $265-$275 million for the full year 2025, representing 2-6% growth over 2024 [2].
GoodRx repurchased 10.2 million shares of Class A common stock for $46.4 million during the quarter, with $143.0 million remaining in its share repurchase program.
References:
[1] https://www.investing.com/news/earnings/goodrx-shares-tumble-as-q2-earnings-miss-expectations-93CH-4174853
[2] https://www.tradingview.com/news/tradingview:ae1287654b1a0:0-goodrx-holdings-inc-sec-10-q-report/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet